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Background: Yearly, millions of children are treated globally with ivermectin mainly for neglected tropical dis-
eases. Anatomical, physiological and biochemical differences between children and adults may result in
changes in pharmacokinetics. However, paediatric pharmacokinetic data of ivermectin are lacking.
Methods: In the framework of a randomized controlled dose-finding trial in rural Coˆte d’Ivoire, Trichuris tri-
chiura-infected pre-school-aged children (PSAC, 2–5 years) and school-aged children (SAC, 6–12 years) were
assigned to 100 or 200lg/kg and 200, 400 or 600lg/kg ivermectin, respectively (ISRCTN registry no.
ISRCTN15871729). Capillary blood was collected on dried blood spot cards until 72 h post-treatment. Ivermectin
was quantified by LC-MS/MS, and pharmacokinetic parameters were evaluated by non-compartmental analysis.
Results: Cmax and AUC increased in PSAC and SAC with ascending doses and were similar in both age groups
when the current standard dose (200lg/kg) was administered (23 ng/mL and 350 ng%h/mL, respectively).
PSAC with lower BMI were associated with significantly higher AUCs. AUC and Cmax were2-fold lower in children
compared with parameters previously studied in adults, whereas body weight-adjusted CL/F (0.35 L/h/kg) was
significantly higher in children. Tmax (6 h), t1/2 (18 h), mean residence time (MRTINF) (28 h) and V/F (8 L/kg)
were similar in all paediatric treatment arms.
Conclusions: A positive association of AUC or Cmax with dose was observed in both age groups. Undernutrition
might influence the AUC of ivermectin in PSAC. Ivermectin shows a lower exposure profile in children compared
with adults, highlighting the need to establish dosing recommendations for different age groups.
Introduction
Ivermectin is an antiparasitic marketed to orally treat onchocercia-
sis and strongyloidiasis, and is used in the combination with alben-
dazole against lymphatic filariasis.1 It is known for its broad
antiparasitic activity and thus is currently being explored as an al-
ternative treatment for rabies, mansonellosis, cancer and other
diseases, as well as as a tool for malaria transmission control.2–5
Additionally, promising efficacy against soil-transmitted helminth
(STH) infections was observed, and the combined therapy of iver-
mectin with the standard drug albendazole has therefore been re-
cently added to the Essential Medicine List for this indication.3 STH
infections belong to the group of neglected tropical diseases and
are caused by infections with Ascaris lumbricoides, hookworms
(Necator americanus, Ancylostoma duodenale and, to a smaller ex-
tent, Ancylostoma ceylanicum) and Trichuris trichiura. A total of
20% of the world’s population are estimated to be infected with at
least one of the STHs, and the parasites are endemic in most coun-
tries of Central and South America, Africa and Asia.6 Annual or bi-
annual large-scale treatment of populations at (high) risk, so-
called targeted preventive chemotherapy, is the current strategy
of the WHO to control the burden of soil-transmitted helminthia-
sis.7–9 However, none of the recommended drugs can effectively
treat T. trichiura.10
Even though ivermectin has been in use since the early 1980s, it
has not been systematically evaluated in human medicine (e.g. for
safety, effective doses and drug disposition in different popula-
tions). To date, pharmacokinetic (PK) studies of ivermectin have
been conducted mostly in a low number of healthy adults or adults
infected with Onchocerca volvulus or Plasmodium falciparum mal-
aria.11–16 Yet, a PK characterization is essential to understand the
human body’s response to a drug, especially in populations that
physiologically differ from healthy adults, such as children.
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Additionally, physiological abnormalities such as malnutrition or
undernutrition and intestinal worms, which are common public
health problems in developing countries, can potentially affect
drug disposition.17 Since most parasitic diseases affect mainly chil-
dren, the characterization of ivermectin’s PK in this age group is ur-
gently needed to apply it safely and effectively to a broad range of
diseases.
For the first time, a PK trial was conducted in rural Coˆte d’Ivoire
with 120 school-aged children (SAC, 6–12 years) and 80 pre-
school-aged children (PSAC, 2–5 years) infected with T. trichiura in
the framework of a phase II dose-finding study. Children were
treated with ascending doses of ivermectin, namely 100 or
200lg/kg for PSAC and 200, 400 or 600lg/kg for SAC. A micro-
blood sampling technique was performed to collect dried blood
spot (DBS) samples over 72 h. Ivermectin was extracted from the
DBS samples and quantified with a previously validated LC-MS/MS
method.18 PK parameters were evaluated and correlated to iver-
mectin’s efficacy against T. trichiura and to anthropological meas-
ures. Finally, PK parameters were compared between the two age
groups and with ivermectin’s PK in adult volunteers, which were
reported previously.18
Materials and methods
Chemicals and material
Ivermectin (powder, 96% B1A), formic acid (LC-MS grade) and ammonium
acetate (LC-MS grade) were purchased from Sigma–Aldrich (Buchs,
Switzerland). Ivermectin-d2 was synthesized by Toronto Research
Chemicals (Ontario, Canada). Ivermectin tablets (3 mg) were kindly pro-
vided by ELEA (Buenos Aires, Argentina). Ivermectin mini-tablets at a
strength of 500lg were produced at the University of Basel.19 Ultrapure
water was prepared using a Millipore water purification system (Milli-QV
R
Advantage A10, Merck, Darmstadt, Germany). LC-MS-grade solvents,
acetonitrile and isopropanol, and WhatmanV
R
protein saver cards 903 were
purchased from Merck KGaA (Darmstadt, Germany). SOLAl solid phase ex-
traction (SPE) plates HRP (hydrophilic reversed phased) were obtained from
Thermo Fisher Scientific (Reinach, Switzerland) and protein low-binding 96-
well plates (PCR clean) were purchased from Vaudaux-Eppendorf AG
(Basel, Switzerland).
Study design, procedure and ethics considerations
The PK study was embedded in a phase II randomized, single-blind trial in
rural Coˆte d’Ivoire with the primary objective of identifying the efficacy of
ascending, single oral doses of ivermectin against T. trichiura infections.
Additionally, the tolerability of the interventions was evaluated by clinical
examinations, assessment of adverse events and blood analysis. Efficacy
and safety data, as well as detailed information on inclusion and exclusion
criteria, randomization procedure and diagnostic methods are published
elsewhere.19 Ethics approval was obtained from the Ethical Committee
of Northwestern and Central Switzerland (2017-00250) and the
Comite´ d’Ethique et de la Recherche of the Ministry of Health in Coˆte
d’Ivoire (052/fMSHP/CNER-kp). The study was registered at the ISRCTN
registry (no. ISRCTN15871729). Volunteers were first invited to information
events and, thereafter, written informed consent was obtained from
parents or guardians of all children, and SAC gave verbal assent.
For the PK study, 80 PSAC (2–5 years of age) and 120 SAC (6–12 years of
age) with T. trichiura infection (.60 eggs/g of stool for PSAC and.100 eggs/g
of stool for SAC) were enrolled in the trial in the setting of Azaguie´, Coˆte
d’Ivoire. Prior to treatment, children were examined for anthropometric
measures, i.e. weight and height. PSAC were randomly assigned to two
treatment arms (100 or 200 lg/kg ivermectin) and SAC to three
treatment groups (200, 400 or 600lg/kg ivermectin). On the treatment
day, participants received a standardized fatty breakfast (oily fish on
bread) owing to ivermectin’s enhanced bioavailability following fatty food
intake.20 Thereafter, ivermectin tablets were orally administered with a
glass of water and treatment time was recorded. SAC received 3 mg tab-
lets and PSAC 0.5 mg mini-tablets according to dose and weight. The
study nurses performed micro-blood sampling at 0, 1, 2, 4, 6, 7, 8, 9, 24,
48 and 72 h post-treatment by taking capillary blood. Sterile finger-
prickers were used to puncture the tip of a finger of the participants to ob-
tain a drop of blood. Lithium heparin-coated capillaries were loaded with
blood, which was subsequently dropped onto DBS cards (60 lL per
spot). This was performed in four replicates for each patient and time-
point. The DBS cards were allowed to dry for at least 2 h and then stored
at room temperature at the clinical trial site in sealed plastic bags con-
taining silica desiccants. DBS samples were shipped to Basel, Switzerland
and stored at#80C until they were processed for analysis.
Sample extraction and analysis by LC-MS/MS
The development, optimization and validation of ivermectin extraction
from DBS samples and the analytical LC-MS/MS method are described else-
where.18 When the DBS samples from participants were analysed, calibra-
tion line samples (3, 5, 10, 25, 50, 80, 100, 150 and 200 ng/mL ivermectin),
quality control samples (six replicates of 3, 5, 100 and 180 ng/mL ivermec-
tin) and blank samples (pure blood extracted from DBS) with internal stand-
ard (ivermectin-d2) were extracted and analysed simultaneously. US FDA
guidelines require a linearity of the calibration line of r2.0.99 and an accur-
acy of 3/4 of calibration line and 2/3 of quality control samples of+15%
[+20% for the lower limit of quantification (LLOQ)] versus the nominal
value.21
Data analysis
PK parameters were obtained by non-compartmental analysis using
WinNonlin (5.2, Certara, Princeton, NJ, USA). Maximum ivermectin concen-
trations (Cmax) and time to reach Cmax (Tmax) were observed values. The
half-life (the time in which half of the absorbed drug is eliminated) was cal-
culated as t1/2"ln(2)/kZ. AUC was determined until the last measurement
(AUC0–72) and until infinity (AUCINF). The area under the first-moment curve
was evaluated until infinity (AUMCINF). AUCs and AUMCINF were calculated
using the linear trapezoidal rule. The mean residence time (MRTINF) was
determined by AUMCINF/AUCINF, and drug clearance (CL/F) was assessed by
dose/AUCINF. CL/F was further adjusted to the participants’ weights. The ap-
parent volume of distribution (V/F) was evaluated by (CL/F)/kZ/kg.
Statistical analysis was performed with GraphPad Prism 6.01
(GraphPad, CA, USA) and Stata Statistical Software: Release 14 (StataCorp
LLC, College Station, TX, USA). Kruskal–Wallis analysis followed by Dunn’s
post-test was performed to compare PK parameters (Cmax, AUC0–72 and CL)
between treatment arms or age groups. Significance (P value) is illustrated
in the figures.
Additionally, a dose–response model of the following form was
estimated:
y ¼ b0 þ b1  x þ ðb2 þ b3  xÞ  dose expðb4Þ;
where x"weight or BMI and y"AUCINF or Cmax. Four specific models were
compared using the Akaike information criterion (AIC): (a) b3, b4 6¼ 0; (b) b3
6¼ 0, b4"0; (c) b3"0, b4 6¼ 0; and (d) b3, b4"0. The model with the lowest AIC
was plotted for different values of weight or BMI. Cure rates represent the
percentage of volunteers who were fully cured (egg negative) after treat-
ment. Egg reduction rates are defined by the group geometric mean reduc-
tion in the number of excreted eggs from baseline (prior to treatment) to
follow-up (2–3 weeks post-treatment) diagnosis.19
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Results
Study participants and micro-blood sampling
Participants’ characteristics are summarized in Table 1. In total,
120 SAC [receiving 200lg/kg (n"41), 400lg/kg (n"39) or 600lg/kg
(n"40)] participated in the PK study, and a complete DBS sample
set was available for the treatment day (0–9 h) and the 24 h
timepoint, but two and four DBS samples at 48 h and 72 h, re-
spectively, could not be collected. A total of 80 PSAC were
enrolled and treated with 100 lg/kg (n"39) or 200 lg/kg (n"41)
ivermectin. In total, nine DBS samples of PSAC were not taken on
the day of treatment (1%2 h, 1%7 h, 3%8 h, 4%9 h), one DBS sam-
ple was missed at each of the 24 and 72 h timepoints and seven
participants were not available for DBS sampling at 48 h.
LC-MS/MS analysis of DBS samples
The calibration line of all experiments fulfilled requirements with r2
.0.994. A minimum of 3/4 of the calibration line and 2/3 of quality
control samples passed accuracy with +15% (+20% for LLOQ)
versus the nominal value. The extraction and analysis of 7% of
samples were repeated and 72% (.2/3) deviated ,20% from the
initial analysed concentrations. The LLOQ for DBS samples is 3 ng/mL.
DBS samples that resulted in,3 ng/mL were set to 0 ng/mL.
PK parameters
The mean concentration–time profiles of ascending doses of iver-
mectin administered to PSAC and SAC are illustrated in Figure 1,
and PK parameters are summarized in Table 2. Cmax increased
with ascending doses, and median values of 15.5 and 24.4 ng/mL
were obtained for PSAC treated with 100 and 200lg/kg ivermec-
tin, respectively, and 21.9, 40.7 and 66.1 ng/mL for SAC treated
with 200, 400 and 600lg/kg ivermectin, respectively. AUCs also
correlated with dose, e.g. AUC0–72 increased from 169 to
369 ng%h/mL in PSAC and from 331 to 880 to 1636 ng%h/mL in
SAC with ascending doses. The median Tmax (5.92–6.80 h), t1/2
(16.3–19.1 h), MRTINF (26.9–29.0 h), V/F (7.46–10.4 L/kg) and CL/F
(5.68–8.58 L/h) were similar in the five treatment arms and thus in-
dependent of dose and age (2–12 years).
AUC or Cmax was computed as a function of absolute dose and
weight or BMI, and the results, grouped by weight or BMI classes,
are illustrated in the supplementary information. AUC as a function
of weight increased dose proportionally in both age groups (Figure
S1, available as Supplementary data at JAC Online). There was a
statistically significant negative association of weight with AUC,
even after adjustment for dose in SAC but not in PSAC. Similar
results were found for BMI in PSAC, whereas the association of BMI
with AUC vanished in SAC after adjustment for dose (Figure S2).
Results for AUC and weight were similar to those for Cmax and
weight in PSAC. The association pattern was more complex in SAC.
Here, Cmax showed a faster than linear increase with ascending
dose and the model including weight and an interaction between
weight and dose provided a significantly better fit than the model
without any weight terms or the model with weight but no inter-
action between dose and weight (Figure S3). The results for BMI
and Cmax resembled those for BMI and AUC in both SAC and PSAC
(Figure S4).
PK–efficacy correlation for T. trichiura infections
Efficacy results are presented as cure rates and egg reduction rates
(Table 2). Whereas correlations between egg reduction rates and
AUC were negligible in SAC and PSAC, a significant positive associ-
ation between ivermectin exposure measured by AUCINF and cure
rate was determined in SAC, with a change in the odds of cure rate
by 8.3% with a 100 ng%h/mL increase in AUCINF (95% CI 0.1%–
17.2%, P"0.047). No significant association was evaluated for
PSAC.
Table 1. Participant characteristics
Parameter PSAC (n"80) SAC (n"120)
Female, n (%) 40 (50) 50 (42)
Age (years) 4 (2–5) 8 (6–12)
Height (cm) 93 (78–111) 121 (91–156)
Weight (kg) 15 (13–18) 22 (12–49)
BMI 16 (12–25) 15 (12–24)
Data are presented as mean (range) unless otherwise stated.
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Figure 1. Mean concentration–time profiles of ascending doses of ivermectin in (a) PSAC and (b) SAC. Weight-dependent doses (lg/kg) are indicated
as numbers in the keys. Results of adult volunteers are illustrated as a comparator.18
Schulz et al.
1644
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/74/6/1642/5374738 by W
W
Z Bibliothek (O
effentliche Bibliothek der U
niversitÃ¤t Basel) user on 05 June 2019
Discussion
Ivermectin is marketed for humans 15 kg (.5 years of age) to
treat onchocerciasis, strongyloidiasis and lymphatic filariasis.
Owing to the lack of an effective treatment against T. trichiura and
other parasitic diseases, ivermectin appears to be a promising drug
candidate with its broad antiparasitic activity. Despite its distribu-
tion to millions of children (.5 years of age), to our knowledge no
paediatric PK characterization has yet been performed. For
the first time, the disposition of ivermectin was evaluated in PSAC
(2–5 years) and SAC (6–12 years) treated with ascending doses.
Whereas drug exposure was similar in children of both age groups
and increased with ascending dosage, AUCs were 2-fold lower in
children than in adults when the same weight-dependent dose
was administered. This finding can have major implications for the
efficacy and safety for paediatric treatment of many diseases.
PK parameters, i.e. Tmax, t1/2, MRTINF, CL/F and V/F, were of simi-
lar value in all treatment arms, highlighting the comparability of
ivermectin’s PK in the age range of 2–12 years. Cmax and AUCs
were similar in PSAC and SAC when the same weight-dependent
dose was administered (200lg/kg ivermectin) (Table 2) and
increased with ascending doses. A statistically significant differ-
ence was observed between the treatment arms among SAC for
Cmax and AUC and among PSAC for Cmax (Figure 2).
A positive association between AUC or Cmax computed with the
absolute dose (mg) and weight was observed in both age groups
(Figures S1–S4). Interestingly, AUCs were significantly higher in
PSAC of lower BMI. Ivermectin is a lipophilic drug and therefore
accumulates in fat tissue. When ivermectin is administered to
patients with higher BMI, it is likely that a larger proportion of iver-
mectin accumulates in fat tissue, leading to smaller amounts
available in the blood and thus to lower AUC values. Helminth
infections affect mostly children living in areas where undernutri-
tion is a common public health problem. With more ivermectin
being available in the blood in young children with a low BMI, sys-
temic drug exposure is raised, possibly resulting in a different effi-
cacy and safety profile; however, further studies are required to
confirm this finding.
Despite moderate egg reduction rates, all doses administered
to SAC and PSAC resulted in low cure rates against T. trichiura
(,21%, Table 2) and in total only 7 SAC and 17 PSAC were cured.19
Nonetheless, logistic regression provided a statistically significant
positive association between ivermectin exposure (AUCINF) and
cure rate in SAC. To date, few PK studies have been conducted in
participants infected with intestinal helminths, and it remains un-
known whether AUC or Cmax or solely intestinal concentrations are
responsible for anthelminthic activity. A recent study in
hookworm-infected children treated with tribendimidine did not
identify a relationship between drug exposure and efficacy.22
Interestingly, the PK results of PSAC and SAC differ from our
own findings in adults when treated with the current standard
dose of 200lg/kg.18 In more detail, Cmax and AUCs are 2-fold
higher in adults than in children (Figure 2). V/F generally depends
on body compartments such as body water or fat content. No dif-
ference in V/F was identified between ivermectin-treated children
(2–12 years) and adults, indicating a similar ratio of body compart-
ments (Table 2). CL/F is similar in all paediatric treatment arms but
significantly higher than CL/F of adults when the values are
adjusted to body weight (Table 2 and Figure S5). Other PKTa
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parameters (t1/2, MRTINF and CL/F) were similar in all treatment
arms of the two paediatric populations but are only approximately
half of the values observed in adults, and Tmax is lower in adults
than in children (3.90 h versus 5.92–6.80 h, Table 2). Of note, our PK
studies with either children or adults were performed in the same
setting in southern Coˆte d’Ivoire, followed the same protocol,
including DBS sampling, and all participants harboured a T. trichiura
infection. Thus, the difference in these results cannot be explained
by study design, infection, procedures or ethnicity of volunteers.
However, only limited information on the PK of ivermectin in
humans is available. Yet, it is widely known that the function and
characteristics of the gastrointestinal tract (e.g. pH, motility and
transit time), hepatic and renal function, and metabolic processes
alter with age and thus can influence the PK of a drug.23,24 Indeed,
age-dependent variation in the PK of ivermectin has been reported
in different animal species, in which ivermectin was studied more
intensively.25 Intestinal motility is decreased in children, causing
impaired transit time (3–7.5 h in children; 3–4 h in adults).26 This
physiological difference might explain the prolonged uptake of iver-
mectin leading to a higher Tmax in children. Moreover, intestinal mo-
tility is responsible for drug–mucosa interaction. If this process is
impaired, a lower amount of ivermectin will be absorbed, causing
lower Cmax and AUC. This might be supported by the lower blood
supply by the superior mesenteric artery to the intestine in children
than in adults (377 and 517 mL/min, respectively).26 Ivermectin is pri-
marily metabolized in the liver, and hepatic damage caused by viral
hepatitis or alcoholism in adults could be an additional explanation of
different ivermectin levels.27 It is worth highlighting that most studies
evaluating physiological development with age are based on
Western standardized body values and do not consider ethnic differ-
ences or the influence of infections and malnutrition.
It has been repeatedly expressed that children are not small
adults and drug dosages cannot be simply extrapolated from
adults to children by adjusting for the body weight. The WHO high-
lighted the need for licensed paediatric drugs as still millions of
children suffer owing to untreated diseases, but barriers for PK tri-
als in children remain high owing to ethical and technical chal-
lenges. PK modelling and simulations based on data derived from
adults might aid in providing paediatric treatment recommenda-
tions. Recently simulated PK parameters of ivermectin of healthy
adults resemble our PK parameters of adults.18,28 However, the
simulated parameters of children based on adults’ data differ from
our results with, for example, predicted approximately double
Cmax and approximately half Tmax.
28 Therefore, the present study
highlights once more that PK clinical trials including paediatric
studies are essential to understanding drugs, especially when
undernutrition and intestinal infections are common.
In summary, a phase II clinical trial was performed in two
paediatric populations (PSAC and SAC) infected with T. trichiura,
and PK parameters of ascending doses of ivermectin were eval-
uated in micro-blood DBS samples. AUC and Cmax increased with
ascending doses, and Tmax, t1/2, MRTINF, CL/F and V/F were dose
and age independent. Malnutrition or undernutrition might influ-
ence the AUC of ivermectin in small children. Ivermectin shows a
lower exposure profile in children than in adults, highlighting the
need to study drug dosing carefully, in particular given the great
interest in applying this drug for novel indications.
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